Business
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026 Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026 Strong Financial Position Funds Operations into Late 20
About this update from Annexon, Inc.
[{"type":"image","alt":"Annexon Biosciences","displaySize":"","headline":null,"caption":"Annexon Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J35LGkHzjL3FW6lOBPAtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/578fc108e7e0712a28769323578aa13e","width":300,"height":99}},"lazy":false},{"type":"text","content":"Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026","length":177,"tagName":"p"},{"type":"text","content":"Vonaprument Pivotal Phase 3 Topline Data for Dry AMD with Geographic Atrophy (GA) on Track for Second Half of 2026 Evaluating Unprecedented Effect on Vision Protection","length":167,"tagName":"p"},{"type":"text","content":"Proof-of-Concept Data for ANX1502, the First Oral C1 Inhibitor for Autoimmune Disease, Expected in 2026","length":103,"tagName":"p"},{"type":"text","content":"Strong Financial Position Funds Operations into Late 2027 Well Past Anticipated Key Milestones","length":94,"tagName":"p"},{"type":"text","content":"BRISBANE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today highlighted its 2026 strategic priorities and key milestones for its lead programs.","length":350,"tagName":"p"},{"type":"text","content":"“2026 is a pivotal year for Annexon as we progress toward our first potential approval in GBS and pivotal Phase 3 data in GA,” said Douglas Love, president and chief executive officer of Annexon. “Building on more than a decade of expertise stopping acute and chronic neuroinflammation at its source, our two registrational programs have both demonstrated meaningful patient benefit in well-controlled trials by significantly protecting function in devastating diseases. As a result, vonaprument and tanruprubart both have the potential to reset the standard of care in their respective diseases and help millions of patients live their best lives.”","length":649,"tagName...